Preliminary, unaudited combined company revenue for the full year 2025 of approximately $185 million; Revenue from continuing operations of approximately $85 millionBOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today announced preliminary and unaudited revenue results for the fourth quarter and full year 2025. Standard BioTools expects fourth quarter 2025 combined company revenue of approximately $56 million and revenue from continuing ...

Core Insights - Standard BioTools Inc. reported financial results for Q3 2025, highlighting a focus on operational efficiency and cost savings initiatives aimed at achieving profitability by 2026 [3][4][7]. Financial Performance - Q3 2025 revenue from continuing operations was $19.6 million, a decrease of 11% year-over-year from $22.1 million in Q3 2024 [6][12]. - Gross margin for Q3 2025 was 48.5%, down from 54.9% in Q3 2024, while non-GAAP gross margin was 53.5%, compared to 57.3% in the same period last year [6][12]. - Operating expenses increased to $42.4 million in Q3 2025, up 9% from $38.8 million in Q3 2024, largely due to restructuring charges [6][12]. - The net loss from continuing operations for Q3 2025 was $31.7 million, compared to a net loss of $21.9 million in Q3 2024, marking a 45% increase in losses [6][12]. Operational Restructuring - The company implemented a phased operational restructuring plan expected to yield over $40 million in annualized cost savings by 2026, including a 20% reduction in workforce [4][5]. - The restructuring aims to enhance operational efficiency and align resources with long-term strategic goals, contributing to a path toward positive adjusted EBITDA in 2026 [4][5]. Cash Position and Future Outlook - As of September 30, 2025, Standard BioTools had $217 million in cash and cash equivalents, with an anticipated increase to approximately $550 million following a pending transaction with Illumina in the first half of 2026 [7][10]. - The company continues to expect full-year 2025 revenue in the range of $165 million to $175 million, with revenue from continuing operations projected between $78 million and $83 million [10]. Market Position and Strategy - Standard BioTools is positioned to expand its portfolio through strategic mergers and acquisitions, leveraging a strong balance sheet and cash reserves to drive growth and deliver long-term shareholder value [3][7].

Group 1 - Standard BioTools Inc. will publish its third quarter 2025 financial results on November 4, 2025, after U.S. market close [1] - The company is a leading provider of next-generation technologies that assist biomedical researchers in developing better medicines more efficiently [2] - Standard BioTools utilizes proprietary technologies such as SomaScan, mass cytometry, and microfluidics to provide insights in health and disease [2] Group 2 - The company collaborates with various sectors including academic, government, pharmaceutical, and biotechnology laboratories globally [2] - Focus areas for Standard BioTools include translational and clinical research, particularly in oncology, immunology, and immunotherapy [2]

Core Viewpoint - Standard BioTools Inc. reported its second quarter 2025 financial results, highlighting a strategic sale of SomaLogic to Illumina, which is expected to unlock up to $425 million in cash and enhance the company's financial position towards profitability by 2026 [3][6][10]. Financial Performance - Revenue for the second quarter of 2025 was $21.8 million, a decrease of 3% year-over-year, while total revenue for the first half of 2025 was $42 million, down 5% year-over-year [4][7]. - Consumables revenue increased by 18% year-over-year to $10.5 million in the second quarter, although total consumables revenue for the first half decreased by 3% to $18.6 million [7][21]. - Instruments revenue fell by 26% year-over-year to $5.2 million in the second quarter, with a slight decrease of 1% to $11.9 million for the first half [13][21]. - Services revenue was $6.1 million in the second quarter, down 8% year-over-year, and $11.5 million for the first half, down 11% year-over-year [13][21]. Gross Margin and Operating Expenses - Gross margin for the second quarter of 2025 was approximately 48.8%, compared to 46.1% in the same quarter of 2024, while non-GAAP gross margin was 54.1%, up from 48.6% [13][22]. - Operating expenses decreased by 11% year-over-year to $36.3 million in the second quarter, with non-GAAP operating expenses down by 1% to $27.9 million [13][23]. - The company achieved a net loss of $17.7 million in the second quarter, an improvement of 31% compared to a net loss of $25.4 million in the same quarter of 2024 [13][25]. Cash Position and Future Outlook - As of June 30, 2025, the company had $239.7 million in cash and cash equivalents, with expectations to reach at least $550 million upon closing the transaction with Illumina [6][19]. - The company is targeting adjusted EBITDA break-even in 2026, supported by a strong balance sheet and a lean operating model [3][6]. Strategic Developments - The sale of SomaLogic is seen as a pivotal milestone for the company, allowing for strategic capital deployment into high-quality assets to drive growth and long-term shareholder value [3][6]. - The company anticipates a high single-digit million decline in Americas academic revenue due to NIH funding pressures, impacting continuing operations more significantly [9]. Revenue Outlook - For fiscal year 2025, the company expects combined revenue in the range of $165 million to $175 million, with revenue from continuing operations projected between $78 million and $83 million [8].

Company Announcement - Standard BioTools Inc. will report its second quarter 2025 financial results on August 11, 2025, after market close [1] - A conference call and webcast will be held on the same day at 4:30 p.m. ET to discuss the financial results and operational progress [1] Access Information - Individuals can access the conference call by dialing US domestic callers: (888) 346-3970 and outside US callers: (412) 902-4297 [1] - Live audio of the webcast will be available on the Investor Relations page of the company's website and will be archived for later access [2] Company Overview - Standard BioTools Inc. is a leading provider of next-generation technologies that assist biomedical researchers in developing better medicines more efficiently [3] - The company utilizes proprietary technologies such as SomaScan, mass cytometry, and microfluidics to provide insights in health and disease, focusing on oncology, immunology, and immunotherapy [3] - Standard BioTools collaborates with various entities including academic, government, pharmaceutical, and clinical laboratories globally [3]

Financial Data and Key Metrics Changes - In Q1 2025, the company reported revenue of $40.8 million, a decrease of 10% year-over-year, attributed to a challenging market environment and elevated backlog from the previous year [9][29] - Non-GAAP gross margins were 53.2%, down from 56.2% in Q1 2024, impacted by lower volume and price realization [32] - The net loss for the quarter was $26 million, an improvement from a net loss of $32.2 million in Q1 2024, representing a 19% improvement [34] - Adjusted EBITDA loss improved to $16.9 million from $23.7 million year-over-year, a 29% improvement [34] Business Line Data and Key Metrics Changes - Consumables revenue was $14.5 million, down 16% year-over-year, primarily due to lower volumes in the Americas Academia segment [29][30] - Instruments revenue increased by 24% year-over-year to $7.8 million, driven by strong demand for spatial proteomics products [30][32] - Services revenue, including lab and field services, was $17.6 million, down 16% year-over-year, with lab services declining by 19% due to backlog gaps [31][32] Market Data and Key Metrics Changes - The Americas market is experiencing a mid-teens percentage decline in academic revenue, with a high single-digit million dollar impact expected [10][36] - International markets and biopharma engagement remain resilient, with continued traction noted in these segments [10][11] Company Strategy and Development Direction - The company is focused on high precision proteomics and expanding its distributed offerings through partnerships, particularly with Illumina [25][66] - A disciplined M&A strategy is in place, with a focus on consolidating the market and leveraging operational synergies [26][48] - The company aims to reach adjusted EBITDA positive by 2026 while maintaining a healthy cash position of $261 million with no material debt [13][35] Management's Comments on Operating Environment and Future Outlook - Management acknowledges a dynamic operating environment but emphasizes a strong internal position with a diversified portfolio and disciplined operating model [8][14] - The company expects the second half of 2025 to be back-weighted in terms of revenue, driven by larger projects in the sales funnel [42][36] - Management remains cautious about the impact of tariffs and macroeconomic conditions but believes they can manage these challenges effectively [11][36] Other Important Information - The company has operationalized $90 million in annualized cost reductions since the merger with SomaLogic, which is crucial for navigating current uncertainties [33] - New product launches at the AACR conference included three new offerings aimed at enhancing the company's market position in proteomics [19][20] Q&A Session Summary Question: Guidance on revenue weighting for 2025 - Management indicated that the revenue is expected to be back half weighted, driven by larger projects in the sales funnel [42] Question: Instrument demand and sales funnel outlook - Management expressed encouragement regarding growth in the sales funnel, particularly for the Hyperion XTI, but refrained from declaring victory due to market uncertainties [43][44] Question: Update on U.S. Academic and government demand - Management confirmed a mid-teens decline in U.S. Academic revenue, with some delays in consumables orders due to funding uncertainties [51][54] Question: Feedback on new product launches - Management noted that the new single soma reagents are now fully available, with expectations for significant long-term opportunities despite initial cautious sales expectations [60][62] Question: Illumina partnership revenue expectations - Management is optimistic about the long-term potential of the Illumina partnership but cautioned that significant revenue growth is not expected in 2025 [65][68] Question: Biopharmaceutical market conditions - Management reported good traction in the biopharma sector, with healthy growth in the sales funnel beyond large customers [69] Question: Impact of cost reduction actions on EBITDA outlook - Management indicated that the recent cost reduction actions would contribute to an improved outlook for adjusted EBITDA losses [70]

Financial Data and Key Metrics Changes - In Q1 2025, the company reported revenue of $40.8 million, a decrease of 10% year-over-year, attributed to a challenging market environment and elevated backlog from the previous year [10][29] - Non-GAAP gross margins were 53.2%, down from 56.2% in Q1 2024, impacted by lower volume and price realization [33] - The net loss for the quarter was $26 million, an improvement from a net loss of $32.2 million in Q1 2024, representing a 19% improvement [35] - Adjusted EBITDA loss improved to $16.9 million from $23.7 million year-over-year, a 29% improvement [35] Business Line Data and Key Metrics Changes - Consumables revenue was $14.5 million, down 16% year-over-year, primarily due to lower volumes in the Americas Academia segment [29] - Instruments revenue increased by 24% year-over-year to $7.8 million, driven by strong sales in spatial proteomics, particularly the Hyperion XTI [30] - Services revenue, including lab and field services, was $17.6 million, down 16% year-over-year, with lab services declining by 19% due to backlog gaps [31] Market Data and Key Metrics Changes - The Americas market is expected to see a mid-teens percentage decline in academic revenue, reflecting ongoing funding uncertainties [11][37] - International markets and biopharma engagement remain resilient, with continued traction noted in these segments [11] Company Strategy and Development Direction - The company is focused on high precision proteomics and expanding its distributed offerings through partnerships, particularly with Illumina, to enhance market leadership [25][66] - A disciplined M&A strategy is in place, with a focus on consolidating technologies and optimizing operations to drive growth [26][49] - The company aims to reach adjusted EBITDA positive by 2026 while maintaining a healthy cash position of $261 million with no material debt [14][35] Management's Comments on Operating Environment and Future Outlook - Management acknowledges a dynamic operating environment but emphasizes a strong internal position with a diversified portfolio and disciplined operating model [8][12] - The company remains committed to long-term profitable revenue growth and increasing shareholder value despite macroeconomic challenges [38] Other Important Information - The company has operationalized $90 million in annualized cost reductions since the merger with SomaLogic, which is crucial for navigating current uncertainties [34] - New product launches at the AACR conference included three new offerings aimed at enhancing the company's service portfolio [20] Q&A Session Summary Question: Guidance on revenue weighting for the year - Management indicated that the revenue is expected to be back half weighted, driven by larger projects in the internal funnel [42][44] Question: Instrument demand and sales funnel outlook - The company is encouraged by growth in the sales funnel, particularly for the Hyperion XTI, but remains cautious about declaring victory [45][46] Question: Update on M&A pipeline and timing - The company remains committed to a disciplined M&A strategy, with a healthy cash position allowing for strategic acquisitions [49] Question: Trends in U.S. Academic and government demand - Management confirmed ongoing challenges in U.S. Academia, maintaining guidance for a mid-teens decline in revenue [52][56] Question: Feedback on new product launches - Initial feedback on new single soma reagents is positive, with expectations for long-term growth potential in this area [58][62] Question: Revenue expectations from the Illumina partnership - While cautious for 2025, management sees long-term potential for significant revenue growth from the Illumina partnership [65][67]

Financial Performance & Outlook - Revenue for Q1 2025 was $40.8 million[10] - The company is targeting revenue in the range of $165 million to $175 million for 2025[10] - Non-GAAP operating expenses decreased by 22% year-over-year in Q1 2025[10, 17, 53] - Adjusted EBITDA improved by 29% year-over-year in Q1 2025[10, 17, 58] - Non-GAAP Gross Margin was 53% in Q1 2025[49] Cash Position & Cost Reduction - The company had $261 million in cash, cash equivalents, restricted cash, and short-term investments as of March 31, 2025[10, 22, 62] - The company operationalized approximately $10 million in cost reductions in Q1 2025, totaling $90 million since the merger[10] Strategic Initiatives - The company is rolling out new proteomics solutions and Illumina NGS[10] - The company is targeting adjusted EBITDA positive in 2026[10, 19, 64] SomaLogic Merger - The company is targeting $80 million in synergies from the SomaLogic merger[19, 22]

Core Insights - Standard BioTools reported a solid first quarter in 2025, achieving a 29% year-over-year improvement in adjusted EBITDA despite a challenging macro environment in Life Sciences [2][5] - The company is focused on its strategic position in proteomics, particularly with the SomaScan and SOMAmers technologies, which are gaining traction in population-based studies [2][5] Financial Performance - Revenue for the first quarter of 2025 was $40.8 million, a decrease of 10% compared to $45.5 million in the first quarter of 2024 [3][6] - Consumables revenue was $14.5 million, down 16% year-over-year, while instruments revenue increased by 24% to $7.8 million, driven by growth in the Hyperion XTi spatial proteomics platform [6][22] - Services revenue totaled $17.6 million, down 16% year-over-year, with Lab Services revenue declining by 19% due to tough comparisons with prior-year levels [6][22] Profitability Metrics - Gross margin for the first quarter of 2025 was 48.4%, down from 53.1% in the same period of 2024, while non-GAAP gross margin was 53.2%, down from 56.2% [3][7] - Operating expenses decreased significantly to $52.7 million, down 38% from $84.4 million in the first quarter of 2024, reflecting cost synergies from the merger [12][24] - The net loss for the first quarter was $26.0 million, an improvement from a net loss of $32.2 million in the first quarter of 2024 [12][26] Cash Position - As of March 31, 2025, the company had a strong balance sheet with $261 million in cash and cash equivalents and no material debt [5][17] - The company operationalized an additional $10 million in annual run rate cost reductions, totaling $90 million since the merger [5][12] Future Outlook - For the fiscal year 2025, Standard BioTools expects revenue in the range of $165 million to $175 million, anticipating a decline in Americas academic revenue due to NIH funding pressures [8][12]

Core Viewpoint - Standard BioTools Inc. is set to report its first quarter 2025 financial results on May 6, 2025, after market close, followed by a conference call to discuss these results and operational progress [1]. Company Overview - Standard BioTools Inc. (Nasdaq: LAB) offers a portfolio of next-generation technologies aimed at accelerating biomedical research and improving medicine development [3]. - The company utilizes proprietary technologies such as SomaScan, mass cytometry, and microfluidics to provide insights into health and disease, facilitating better patient outcomes [3]. - Standard BioTools collaborates with various sectors including academic, government, pharmaceutical, and biotechnology research, focusing on critical areas in translational and clinical research like oncology and immunology [3].